Targeting Lipoprotein(a) to reduce residual risk in high risk atherosclerotic cardiovascular disease patients. Rev. Fed. Arg. Cardiol. [Internet]. 2023 Jun. 29 [cited 2024 Jul. 3];52(2):59-64. Available from: https://revistafac.org.ar/ojs/index.php/revistafac/article/view/499